Business

Incannex Healthcare Expands Clinical Advisory Board to Support Obstructive Sleep Apnea Program with Appointment of Dr. Charlene E. Gamaldo

NEW YORK and MELBOURNE, Australia, July 25, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL) (“Incannex” or the “Company”), a clinical-stage biopharmaceutical company advancing combination drug therapies for high-impact indications, announces the appointment of Charlene E. Gamaldo, M.D. to its IHL-42X Obstructive Sleep Apnea (OSA) Clinical Advisory Board. Incannex Chief Medical Officer Dr. Lou Barbato commented:“We are fortunate to welcome Dr. Gamaldo to the Incannex Clinical Adv

articleIncannex Healthcare Inc.July 25, 20257/company/incannex-healthcare-ltd-adr/news/incannex-healthcare-expands-clinical-advisory-113000308
Incannex Healthcare Expands Clinical Advisory Board to Support Obstructive Sleep Apnea Program with Appointment of Dr. Charlene E. Gamaldo

About this update from Incannex Healthcare Inc.

[{"type":"image","alt":"Incannex Healthcare","displaySize":"","headline":null,"caption":"Incannex Healthcare","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":50,"url":"https://media.zenfs.com/en/globenewswire.com/27f6059234ed425fa359634ca773e7f7"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/JtZ_G8jXkVENc6BFL9UpGQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTcwO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/27f6059234ed425fa359634ca773e7f7","width":300,"height":50}},"lazy":false},{"type":"text","content":"NEW YORK and MELBOURNE, Australia, July 25, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL) (“Incannex” or the “Company”), a clinical-stage biopharmaceutical company advancing combination drug therapies for high-impact indications, announces the appointment of Charlene E. Gamaldo, M.D. to its IHL-42X Obstructive Sleep Apnea (OSA) Clinical Advisory Board.","length":373,"tagName":"p"},{"type":"text","content":"Incannex Chief Medical Officer Dr. Lou Barbato commented:“We are fortunate to welcome Dr. Gamaldo to the Incannex Clinical Advisory Board. Her leadership across neurology, psychiatry, and public health, combined with a distinguished track record in sleep medicine, brings tremendous value to our obstructive sleep apnea program. With the highly anticipated Phase 2 data readout for IHL-42X expected next week, Dr. Gamaldo’s appointment reflects our growing confidence in the asset and our commitment to advancing its development with scientific rigor and operational excellence.”","length":580,"tagName":"p"},{"type":"text","content":"Dr. Charlene E. Gamaldo is a Professor at Johns Hopkins School of Medicine with joint appointments in psychiatry, nursing, anesthesiology, and public health. She serves as Vice Chair for Faculty Development in the Neurology Department and as Associate Vice Provost of the Johns Hopkins Provost’s Leadership, Advancement and Development Academy.","length":344,"tagName":"p"},{"type":"text","content":"Dr. Gamaldo earned her Bachelor of Arts in Psychology from the University of Virginia and her medical degree from The George Washington University School of Medicine. Following her neurology residency at the University of North Carolina Hospital, she became the first neurology sleep fellow at Johns Hopkins in 2004.","length":316,"tagName":"p"},{"type":"text","content":"Since ...

More updates from Incannex Healthcare Inc.

Charlene E. GamaldoObstructive Sleep ApneaIncannex Healthcare Inc.Incannex Clinical Advisory Boardclinical careclinical trialJohns HopkinsDrIncannex Healthcare IncAmerican Academy of Neurology